Scisparc Ltd (SPRC)

$2.56 -0.22 (-7.91%)
Market Cap 1.49M
Revenue (ttm) 1.31M
Net Income (ttm) -6.28M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -479.39%
Debt to Equity Ratio 0.04
Volume 16,200
Avg Vol 5,652,432
Day's Range N/A - N/A
Shares Out 535,000.00
Stochastic %K 6%
Beta 1.12
Analysts Strong Buy
Price Target $20.00

Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. It also sells hemp seed oil-based products and others. The company has an agreement with Procaps to develop and commercially manufac...

Industry: Biotechnology
Sector: Healthcare
Phone: 972 7 334 47180
Address:
Tower A, 2nd Floor 20 Raul Wallenberg Street, Tel Aviv, Israel
MovingFast77
MovingFast77 Nov. 14 at 3:24 AM
$SPRC $6.75
0 · Reply
CometaMan
CometaMan Nov. 13 at 12:31 PM
$SPRC when will this ticker lift up? Bring back the $4 s
0 · Reply
MovingFast77
MovingFast77 Nov. 6 at 3:00 PM
$SPRC payment coming
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 5 at 2:19 PM
$SPRC $DNA $ALBT $MAXN making changes to u 4
0 · Reply
416traders
416traders Nov. 4 at 1:03 PM
$SPRC https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319549341&type=HTML&symbol=SPRC&cdn=d611f099e417855eb771373c7d0f281a&companyName=SciSparc+Ltd.&formType=RW&formDescription=Registration+Withdrawal+Request&dateFiled=2025-11-04
0 · Reply
CometaMan
CometaMan Oct. 29 at 6:03 PM
$ENTO Nice bounce. $SPRC is next. Let's do it! I am ento ENTO🐯
0 · Reply
DanielSmith310
DanielSmith310 Oct. 29 at 4:57 PM
$SPRC growing resilience; AITX growing recognition — RAD’s AI-powered ecosystem showing measurable real-world safety gains.
0 · Reply
PiratesKingLuffy
PiratesKingLuffy Oct. 29 at 2:16 AM
All eyes will be on ticker SSKN tomorrow. SSKN had massive news today! Be ready tomorrow bulls, SSKN has potential to see a 300-400%+ rally! SSKN 🔹Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements 🔹Partnership with MINO Labs gives access to a network of ~3,000 dermatologists 🔹Very Low Float/ OS near 4M shares $PONY $IPST $DDD $SPRC
0 · Reply
JimBull
JimBull Oct. 28 at 8:18 PM
$NITO 13-G file, $SPRC is also shareholder now.
2 · Reply
MovingFast77
MovingFast77 Oct. 28 at 2:46 PM
$SPRC will explode upwards in the next week great entry point
0 · Reply
Latest News on SPRC
SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 24, 2025, 7:55 AM EDT - 21 days ago

SciSparc Announces Closing of the Acquisition of a Publicly Traded Company on the TSXV to which it transferred its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Oct 23, 2025, 4:03 PM EDT - 21 days ago

SciSparc Announces Closing of the Sale to N2OFF of Majority-Owned Subsidiary MitoCareX, Advancing Drug Discovery for Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Oct 23, 2025, 8:55 AM EDT - 22 days ago

SciSparc Targets Quantum-Powered 3D Protein Modeling Technology to Revolutionize AI Drug Discovery

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

Oct 22, 2025, 3:30 PM EDT - 22 days ago

Scisparc Ltd. - Early Warning Regarding Acquisition Of Common Shares Of Neurothera Labs Inc.

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

Oct 20, 2025, 7:41 AM EDT - 25 days ago

SciSparc-Clearmind Collaboration Leads to Publication of U.S. Patent Application Targeting Binge Behavior Disorders

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

Oct 15, 2025, 7:05 AM EDT - 4 weeks ago

SciSparc Enters into Definitive Agreement for the Acquisition of a Publicly Traded Company on the TSXV to which it will transfer its Advanced Clinical Stage Pharmaceutical Portfolio

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

Oct 6, 2025, 6:40 AM EDT - 5 weeks ago

SciSparc Ltd. Announces Framework Agreement Regarding Merger with AutoMax Motors

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

Sep 29, 2025, 4:03 PM EDT - 6 weeks ago

SciSparc: N2OFF Shareholders Approve Merger with SciSparc's Majority Owned Subsidiary MitoCareX, a Drug Discovery Company Targeting Resistant Cancers Including Pancreatic and Non-Small Cell Lung Cancer

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

Sep 25, 2025, 1:06 PM EDT - 7 weeks ago

SciSparc Stock Surges As It Launches Initiative To Advance Drug Discovery With Quantum Algorithms

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

Sep 25, 2025, 7:05 AM EDT - 7 weeks ago

SciSparc Resolves to Launch Innovative Quantum Computing-Enabled 3D Protein Modeling Initiative to Revolutionize AI Drug Discovery

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

Aug 28, 2025, 9:24 AM EDT - 2 months ago

SciSparc: AutoMax's Shareholders Approve Merger with SciSparc

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

Aug 28, 2025, 6:45 AM EDT - 2 months ago

SciSparc Shareholders Approve Merger with a Leading Parallel Vehicle Importer in Israel

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

Aug 7, 2025, 7:32 AM EDT - 3 months ago

SciSparc-Clearmind Collaboration Leads to Publication of International Patent Application for Novel Combination Therapy Targeting Obesity and High Blood Sugar

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

Jul 30, 2025, 4:34 PM EDT - 3 months ago

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

Jul 30, 2025, 8:12 AM EDT - 3 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

Jul 22, 2025, 7:32 AM EDT - 4 months ago

SciSparc Ltd. Regains Compliance with Nasdaq Minimum Bid Price Notification

SciSparc Announces 1-for-21 Reverse Share Split

Jun 24, 2025, 5:03 PM EDT - 5 months ago

SciSparc Announces 1-for-21 Reverse Share Split

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025, 7:32 AM EDT - 6 months ago

SciSparc Announces Publication of Japanese Patent Application

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

Apr 25, 2025, 7:59 AM EDT - 7 months ago

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

CMND

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

Mar 3, 2025, 8:25 AM EST - 9 months ago

SciSparc Signs Definitive Agreement to Sell MitoCareX, Computational Drug Discovery Company Targeting Resistant Cancers

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

Feb 27, 2025, 8:45 AM EST - 9 months ago

SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

Feb 18, 2025, 7:17 AM EST - 9 months ago

SciSparc Secures Favorable Settlement in Lawsuit It Filed, Receiving Cash Compensation and a Full Release from All Commitments, Royalties, and Allegations Asserted Against It on Claimed Core Technology

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

Feb 4, 2025, 9:00 AM EST - 10 months ago

SciSparc-Clearmind Collaboration Leads to Publication of Patent for Binge Behaviour Combination Treatment in Mexico

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

Jan 15, 2025, 7:34 AM EST - 10 months ago

SciSparc Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Requirement

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

Jan 13, 2025, 8:41 AM EST - 10 months ago

SciSparc: AutoMax Enters the Direct Import Market with a $13 Million First Shipment of JAC Electric Vehicles

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Jan 7, 2025, 7:25 AM EST - 11 months ago

SciSparc: MitoCareX Bio Expands Research to Pancreatic Cancer Following Initial In-Vitro Positive Results

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

Jan 6, 2025, 11:04 AM EST - 11 months ago

Why Is Psychedelic-SciSparc Stock Trading Higher On Monday?

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

Jan 6, 2025, 7:50 AM EST - 11 months ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of European Patent Application for Binge Behavior Psychedelic Combination Treatment

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

Dec 31, 2024, 9:24 AM EST - 11 months ago

SciSparc Announces Renewal of Approval by Israeli Medical Cannabis Agency for its Clinical Trial in Children with Autism Spectrum Disorder

S&P 500 Edges Lower, SciSparc Shares Surge

Dec 26, 2024, 2:36 PM EST - 11 months ago

S&P 500 Edges Lower, SciSparc Shares Surge

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

Dec 26, 2024, 6:46 AM EST - 11 months ago

SciSparc: AutoMax Announces $13 Million First Delivery of JAC Vehicles Following Regulatory Approval for Direct Importation

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

Dec 16, 2024, 7:40 AM EST - 11 months ago

SciSparc Provides Updates on Status of Spin-off of its Advanced Clinical Stage Pharmaceutical Portfolio to a Publicly Traded Company

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

Sep 30, 2024, 9:25 AM EDT - 1 year ago

SciSparc Secures FDA Green Light to US Launch of its Pivotal Phase IIb Clinical Trial for Breakthrough Tourette Syndrome Treatment

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

Sep 26, 2024, 9:05 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent to Sell Stake in MitoCareX

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 23, 2024, 8:17 AM EDT - 1 year ago

SciSparc Receives FDA Approval to Initiate Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

Sep 18, 2024, 4:09 PM EDT - 1 year ago

SciSparc Takes Major Step Forward with IND Application submitted to the FDA for Phase IIb Clinical Trial for Tourette Syndrome Treatment

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

Sep 16, 2024, 4:06 PM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Announces the Publication of an International Patent Application for Pioneering Ibogaine Combination Therapy

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

Sep 11, 2024, 7:40 AM EDT - 1 year ago

SciSparc Advances $1.85 million Loan to AutoMax, Following AutoMax's Direct Import Agreement with Major Chinese Vehicle Manufacturer

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

Sep 6, 2024, 7:55 AM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of International Patent Application for Innovative MDMA-Based Combination Treatment

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

Aug 29, 2024, 4:25 PM EDT - 1 year ago

SciSparc-Clearmind Medicine Collaboration Leads to Publication of Application for Innovative Ketamine-Based Combination

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

Aug 28, 2024, 8:55 AM EDT - 1 year ago

SciSparc Grants Global Rights for Pain Therapy to Biotech Company in Agreement Worth up to $6 Million

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

Aug 23, 2024, 4:09 PM EDT - 1 year ago

SciSparc Submitted IND Application to the FDA for SCI-110 Phase IIb Clinical Trial for Patients with Tourette Syndrome

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Aug 22, 2024, 8:12 AM EDT - 1 year ago

SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

Aug 19, 2024, 4:11 PM EDT - 1 year ago

SciSparc Announces Enrollment of the First Five Patients in the Clinical Trial of its Innovative SCI-210 Treatment

Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy

Aug 19, 2024, 7:51 AM EDT - 1 year ago

Israeli Penny Stock Biotech SciSparc Outlicenses Its Cannabinoid Pain Therapy

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

Aug 16, 2024, 4:30 PM EDT - 1 year ago

SciSparc Finalizes Exclusive Global Out-Licensing Agreement for its Pain Therapy Valued at $3 million

SciSparc Updates Regarding the Status of the AutoMax Merger

Aug 14, 2024, 4:53 PM EDT - 1 year ago

SciSparc Updates Regarding the Status of the AutoMax Merger

SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

Aug 6, 2024, 8:57 AM EDT - 1 year ago

SciSparc's Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

Jul 22, 2024, 8:20 AM EDT - 1 year ago

SciSparc: MitoCareX Confirms Potential Significant Role of its Drug Target in Non-Small Cell Lung Cancer

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

Jul 17, 2024, 7:07 AM EDT - 1 year ago

SciSparc Signs Non-Binding Letter of Intent for Exclusive Global Out-Licensing of Pain Treatment for Approximately $6 million

MovingFast77
MovingFast77 Nov. 14 at 3:24 AM
$SPRC $6.75
0 · Reply
CometaMan
CometaMan Nov. 13 at 12:31 PM
$SPRC when will this ticker lift up? Bring back the $4 s
0 · Reply
MovingFast77
MovingFast77 Nov. 6 at 3:00 PM
$SPRC payment coming
0 · Reply
Love_To_Learn
Love_To_Learn Nov. 5 at 2:19 PM
$SPRC $DNA $ALBT $MAXN making changes to u 4
0 · Reply
416traders
416traders Nov. 4 at 1:03 PM
$SPRC https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&ref=319549341&type=HTML&symbol=SPRC&cdn=d611f099e417855eb771373c7d0f281a&companyName=SciSparc+Ltd.&formType=RW&formDescription=Registration+Withdrawal+Request&dateFiled=2025-11-04
0 · Reply
CometaMan
CometaMan Oct. 29 at 6:03 PM
$ENTO Nice bounce. $SPRC is next. Let's do it! I am ento ENTO🐯
0 · Reply
DanielSmith310
DanielSmith310 Oct. 29 at 4:57 PM
$SPRC growing resilience; AITX growing recognition — RAD’s AI-powered ecosystem showing measurable real-world safety gains.
0 · Reply
PiratesKingLuffy
PiratesKingLuffy Oct. 29 at 2:16 AM
All eyes will be on ticker SSKN tomorrow. SSKN had massive news today! Be ready tomorrow bulls, SSKN has potential to see a 300-400%+ rally! SSKN 🔹Announces COFEPRIS Clearance of TheraClear® in Mexico and First Commercial Placements 🔹Partnership with MINO Labs gives access to a network of ~3,000 dermatologists 🔹Very Low Float/ OS near 4M shares $PONY $IPST $DDD $SPRC
0 · Reply
JimBull
JimBull Oct. 28 at 8:18 PM
$NITO 13-G file, $SPRC is also shareholder now.
2 · Reply
MovingFast77
MovingFast77 Oct. 28 at 2:46 PM
$SPRC will explode upwards in the next week great entry point
0 · Reply
MovingFast77
MovingFast77 Oct. 28 at 12:52 PM
$SPRC
0 · Reply
CometaMan
CometaMan Oct. 27 at 4:36 PM
Loading up some $ENTO at today pricing under 4.05. The same for $SPRC under $3.80 🙂
0 · Reply
Trader1141
Trader1141 Oct. 24 at 11:12 PM
$GNPX I see some of you loaded up for Monday am… tomorrow positive data presentation 👍🏽 $WGRX $SPRC $SPRB $ASST
1 · Reply
Chinna11
Chinna11 Oct. 24 at 7:57 PM
$SPRC all need is volume
0 · Reply
Chinna11
Chinna11 Oct. 24 at 7:56 PM
$SPRC after hours gonna spike again
0 · Reply
Chinna11
Chinna11 Oct. 24 at 3:30 PM
$SPRC need volume along with the recent couple news
0 · Reply
EZ_Money11
EZ_Money11 Oct. 24 at 12:13 PM
$SPRC
0 · Reply
OTCshithead
OTCshithead Oct. 24 at 12:02 PM
$SPRC Agreed.
0 · Reply
BullsEye2000
BullsEye2000 Oct. 24 at 12:00 PM
$SPRC nah, don’t trust it or want to even consider paying money into a genocide. These plays from a certain somewhere always end up in rug pulls anyways.
1 · Reply
makedatbread88
makedatbread88 Oct. 24 at 11:58 AM
$SPRC low floater with news!
0 · Reply
Chinna11
Chinna11 Oct. 23 at 8:08 PM
$SPRC this will reach $6 tomorrow
0 · Reply